Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1111/apa.14195 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Neonatal encephalopathy due to suspected hypoxic ischemic encephalopathy: pathophysiology, current, and emerging treatments.
World J Pediatr
November 2024
SAMRC Extramural Unit for Stem Cell Research and Therapy, Department of Immunology, Faculty of Health Sciences, Institute for Cellular and Molecular Medicine, University of Pretoria, Room 5-64, Level 5, Pathology Building, 15 Bophelo Road (Cnr. Steve Biko and Dr. Savage Streets), Prinshof Campus, Gezina, Pretoria, South Africa.
Background: Neonatal encephalopathy (NE) due to suspected hypoxic-ischemic encephalopathy (HIE), referred to as NESHIE, is a clinical diagnosis in late preterm and term newborns. It occurs as a result of impaired cerebral blood flow and oxygen delivery during the peripartum period and is used until other causes of NE have been discounted and HIE is confirmed. Therapeutic hypothermia (TH) is the only evidence-based and clinically approved treatment modality for HIE.
View Article and Find Full Text PDFEarly and extended erythropoietin monotherapy after hypoxic ischaemic encephalopathy: a multicentre double-blind pilot randomised controlled trial.
Arch Dis Child Fetal Neonatal Ed
October 2024
Centre for Perinatal Neuroscience, Department of Brain Sciences, Imperial College London, London, UK.
Objective: To examine the feasibility of early and extended erythropoietin monotherapy after hypoxic ischaemic encephalopathy (HIE).
Design: Double-blind pilot randomised controlled trial.
Setting: Eight neonatal units in South Asia.
Metastatic breast cancer with double heterozygosity for the and genes responding to olaparib: A case report.
Oncol Lett
June 2024
Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Breast Oncology, Peking University Cancer Hospital and Institute, Beijing 100142, P.R. China.
Olaparib was the first poly ADP-ribose polymerase inhibitor approved for patients with cancer with mutations in either or in China. To the best of our knowledge, however, no study has described the efficacy of olaparib for patients with breast cancer with double mutations in and . The present case report describes a patient with breast cancer with deleterious germline mutations in both and .
View Article and Find Full Text PDFArticle Synopsis
- Erythropoietin (EPO) is being studied as a potential treatment for newborns with hypoxic-ischemic encephalopathy (HIE), showing mixed results regarding its safety and effectiveness.
- A meta-analysis of seven studies involving 903 infants found that EPO did not significantly decrease the risk of death, neurodisability, or cerebral palsy in these patients.
- The findings suggest that EPO may not be an effective treatment for neonatal encephalopathy, highlighting the need for further large-scale randomized controlled trials to confirm these results.
Novel Combination of Erythropoietin and Romiplostim to Treat Chemotherapy-Induced Anemia and Thrombocytopenia via Pharmacodynamic Interaction on Hematopoietic Stem and Progenitor Cells.
ACS Pharmacol Transl Sci
December 2023
School of Pharmacy, Faculty of Medicine, The Chinese University of Hong Kong, Shatin, Hong Kong 999077, China SAR.
Chemotherapy-induced anemia and thrombocytopenia (CIAT) in cancer patients are often caused by the damage of hematopoietic stem and progenitor cells (HSPCs) in the bone marrow. We have previously shown that romiplostim, a thrombopoietin receptor agonist that could stimulate the expansion of HSPCs, could synergize with recombinant human erythropoietin (rHuEPO) to promote erythropoiesis in addition to stimulating platelet production, whereas rHuEPO could influence the platelet count through stem cell competition. Therefore, we hypothesize that a combination of romiplostim with rHuEPO can alleviate CIAT simultaneously, while minimizing the risk of thrombosis.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!